mRNA vaccines — a new era in vaccinology
By N. Pardi, Michael J. Hogan, F. Porter, D. Weissman. Nature reviews. Drug discovery, 2018
3,917 citations recorded by the source corpus.
mRNA vaccines represent a promising alternative to conventional vaccine approaches because of their high potency, capacity for rapid development and potential for low-cost manufacture and safe administration. However, their application has until recently been restricted by the instability and inefficient in vivo delivery of mRNA. Recent technological advances have now largely overcome these issues, and multiple mRNA vaccine platforms against infectious diseases and several types of cancer have demonstrated encouraging results in both animal models and humans. This Review provides a detailed overview of mRNA vaccines and considers future directions and challenges in advancing this promising vaccine platform to widespread therapeutic use.
Subfields: Animal Science and Zoology, Immunology, Molecular Biology
View Paper: https://www.semanticscholar.org/paper/5e2f349c96793e6575615cf81b08b55f8694b50e
How researchers see this paper
The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.
In Immunology
- E. Wherry
- Michael J. Hogan
- N. Pardi
- Rafi Ahmed
- A. Schietinger
- P. Greenberg
- J. Snyder-Cappione
- Anna C. Belkina
In Molecular Biology
Citations in the corpus
- mRNA-based therapeutics: powerful and versatile tools to combat diseases (2022, background): “Importantly, mRNA has no potential risk of accidental infection or opportunistic insertional mutagenesis.(6) In addition, mRNA has broad potential for treating diseases requiring protein expression and higher therapeutic efficacy due to its continuous translation into encoded proteins/peptides to tr”
- Neoantigens: promising targets for cancer therapy (2023, neutral): “The 5′ cap structure, the length of 3′ poly(A) tail and regulatory elements in the untranslated regions have all been optimized for this purpose.(177,341) Efficient intracellular delivery is also required for effective mRNA therapies in vivo.”
- Interpretable RNA Foundation Model from Unannotated Data for Highly Accurate RNA Structure and Function Predictions (2022, background): “Determination of RNA structure or type is also an essential part of RNA-based therapeutics, including mRNA vaccines, RNA interference and CRISPR-based therapeutics [4–6].”
- Distinct antibody and memory B cell responses in SARS-CoV-2 naïve and recovered individuals following mRNA vaccination (2021, background): “tion by the FDA and are being widely administered (2, 3).”
- mRNA Vaccines in the COVID-19 Pandemic and Beyond. (2021, background): “, protein kinase RNA-activated (PKR) and 2′-5′-oligoadenylate synthetase (OAS)] (61, 62), leading to a signaling cascade that significantly dampens protein expression (3).”